I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.

Northwest Bio (NWBO) reprices warrants to raise cash

August 23, 2016

Raises $1.279 M as the stock price dumps -$0.06 to $0.34. The question is how long will this tranche of cash forestall insolvency? NWBO’s “saga” rolls on.  

Stemline Therapeutics (STML) receives Breakthrough Therapy Designation from U.S. FDA for SL-401

August 23, 2016

STML closed FLAT at $7.40 and is UP in the ppre-open +$1.99 or +26.89% - BUY  

Mesoblast (MESO) Rheumatic diseases patent award drives stock pricing

August 17, 2016

+$0.42 or +8.07% to $6.12 post open - after the applause pricing will slip  

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.